- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05885503
Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema
August 30, 2023 updated by: RemeGen Co., Ltd.
A Phase III, Multicenter, Randomized, Double-blind, Active Controlled Trial of RC28-E Intravitreal Injection in Subjects With Diabetic Macular Edema
The purpose of this study is to evaluate efficacy and safety of RC28-E compared with Aflibercept in subjects with diabetic macular edema.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
316
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Binghua Xiao
- Phone Number: 86-010-58076833
- Email: xiaosir522@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100010
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Youxin Chen, M.D.
- Phone Number: 13801025972
- Email: chenyouxinpumch@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Documented diagnosed with type I or type II diabetes mellitus.
- Hemoglobin A1c (HBA1c) of less than or equal to (≤) 10% within 2 months prior to Day 1.
- Ability and willingness to undertake all scheduled visits and assessments.
The study eye must meet the following requirements:
- macular thickening secondary to diabetic macular edema (DME) involving the center of the fovea.
- decreased visual acuity attributable primarily to DME, the best corrected visual acuity (BCVA) 19 or more letters, 78 letters or less.
Exclusion Criteria:
- The study eye with high risk of proliferative diabetic retinopathy.
- The macular edema of the study eye is mainly caused by other diseases or factors other than DME.
- Treatment with panretinal photocoagulation or macular laser within 3 months prior to Day 1 to the study eye.
- Administration of IVT any other anti-VEGF drugs in the study eye within 3 months and/or in the other eye within 7 days prior to Day 1.
- Any intraocular long-acting or sustained release corticosteroid treatment (e.g., dexamethasone intravitreal implant) in the study eye within 6 months prior to Day 1.
- Active intraocular or periocular infection or active intraocular inflammation in either eye.
- The study eye with poorly controlled glaucoma.
- A history of idiopathic or autoimmune related uveitis in either eye.
- History of stroke (cerebrovascular accident) or myocardial infarction within 6 months prior to Day 1.
- Uncontrolled blood pressure, defined as a systolic value greater than (>)180 millimeters of mercury (mmHg) and/or a diastolic value >100 mmHg while a patient is at rest.
- Currently pregnant or breastfeeding, or intend to become pregnant during the study.
- Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision in the study eye.
- Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than DME in the study eye.
- Other protocol-specified inclusion/exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RC-28E
RC-28E 2.0 mg will be initially intravitreal injected (IVT) 5 times at 4 week intervals from week 0 to week 16, then every 8 weeks until week 48.
|
Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
|
Active Comparator: Aflibercept
Aflibercept 2.0mg will be received IVT once every 4 weeks for 5 consecutive times from week 0 to week 16, then once every 8 weeks till week 48.
|
Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in BCVA at Week 52
Time Frame: Baseline, week 52
|
BCVA=best-corrected visual acuity; Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts at a starting distance of 4 meters
|
Baseline, week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average change in BCVA from baseline over the period week 40 through week 52
Time Frame: Baseline, weeks 40, 44, 48 and 52
|
For each subject, this endpoint is defined as the average of the changes from baseline to weeks 40, 44, 48 and 52
|
Baseline, weeks 40, 44, 48 and 52
|
Change from baseline in BCVA over time
Time Frame: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
|
BCVA will be assessed at each visit
|
Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
|
Proportion of patients gaining >15, >10, >5, or >0 letters in BCVA from baseline at Week 52
Time Frame: Baseline, week 52
|
Proportion of patients of gaining 4 types of letter counting in BCVA, respectively
|
Baseline, week 52
|
Proportion of patients avoiding a loss of >15, >10, >5, or >0 letters in BCVA from baseline at Week 52
Time Frame: Baseline, week 52
|
Proportion of patients of reducing 4 types of letter counting in BCVA, respectively
|
Baseline, week 52
|
Change from baseline in CST at Week 52
Time Frame: Baseline, week 52
|
CST=central subfield thickness
|
Baseline, week 52
|
Mean change from baseline in CST over a period of week 40 through week 52
Time Frame: Baseline, weeks 40, 44, 48 and 52.
|
CST=central subfield thickness
|
Baseline, weeks 40, 44, 48 and 52.
|
Change from baseline in CST over time
Time Frame: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
|
The change of CST will be assessed from baseline to 52 weeks by every 4 week intervals
|
Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
|
Proportion of patients with absence of intraretinal fluid at Week 52
Time Frame: Baseline, week 52
|
Proportion of patients whose intraretinal fluid are completely improved
|
Baseline, week 52
|
Proportion of patients with absence of subretinal fluid at Week 52
Time Frame: Baseline, week 52
|
Proportion of patients whose subretinal fluid are completely improved
|
Baseline, week 52
|
Proportion of patients with absence of intraretinal fluid and subretinal fluid at Week 52
Time Frame: Baseline, week 52
|
Proportion of patients whose intraretinal fluid and subretinal fluid are both completely improved
|
Baseline, week 52
|
Proportion of patients with a >2-step or>3-step DRS worsening from baseline on ETDRS DRSS at Week 52
Time Frame: Baseline, week 52
|
DRSS=Diabetic Retinopathy Severity Scale
|
Baseline, week 52
|
Proportion of patients who develop new PDR or high risk PDR at Week 52
Time Frame: Baseline, week 52
|
PDR=proliferative diabetic retinopathy
|
Baseline, week 52
|
Incidence and severity of ocular adverse events and non-ocular adverse events
Time Frame: 0~52 weeks
|
during the study
|
0~52 weeks
|
Plasma concentration of RC28-E over time
Time Frame: Baseline, weeks 16, 36 and 48
|
during the study
|
Baseline, weeks 16, 36 and 48
|
Presence of ADAs during the study relative to the presence of ADAs at baseline
Time Frame: Baseline, weeks 12, 24, 36 and 52
|
during the study
|
Baseline, weeks 12, 24, 36 and 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Youxin Chen, Peking Union Medical College Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 8, 2023
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
June 1, 2026
Study Registration Dates
First Submitted
May 19, 2023
First Submitted That Met QC Criteria
May 30, 2023
First Posted (Actual)
June 2, 2023
Study Record Updates
Last Update Posted (Actual)
September 5, 2023
Last Update Submitted That Met QC Criteria
August 30, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 28C005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
Clinical Trials on RC-28E
-
Dennis Turner, M.D.National Institute of Neurological Disorders and Stroke (NINDS); National Institutes...Completed
-
Helsinn Therapeutics (U.S.), IncCompletedCancer CachexiaUnited States
-
MedtronicNeuroCompletedParkinson's Disease | Dystonia | Essential TremorUnited States, France, Spain, Germany, United Kingdom, Austria
-
University of WaterlooBausch & Lomb IncorporatedUnknown
-
RemeGen Co., Ltd.RecruitingPrimary Sjogren's SyndromeChina
-
US Department of Veterans AffairsCompleted
-
Princess Maxima Center for Pediatric OncologyEuropean CommissionRecruitingAcute Myeloid Leukemia in ChildrenNetherlands
-
Sunnybrook Health Sciences CentreUniversity Health Network, Toronto; Princess Margaret Hospital, Canada; Toronto...CompletedHead and Neck NeoplasmsCanada
-
Rush University Medical CenterWithdrawnChronic Obstructive Pulmonary Disease (COPD)
-
Helsinn Therapeutics (U.S.), IncCompletedCancer CachexiaUnited States